Track genome-wide copy number variation
for safer cell therapy development and better insights into cancer drivers.
for safer cell therapy development and better insights into cancer drivers.
Get determinative insights into clonal heterogeneity driving disease progression and therapy response in multiple myeloma, even at its earliest stages.
Reveal the heterogeneity of gene edits at single-cell resolution, including on- and off-target edits, translocations, and zygosity of edits.
From drug development and clinical research to commercial manufacturing and release testing, PAD provides end-to-end support to accelerate your precision medicine and cell and gene therapy programs.
Providing cancer researchers with the only single-cell technology that simultaneously measures single nucleotide variation (SNV), copy number variation (CNV), and protein data from the same cells. Our multi-omics platform connects genotype and phenotype in each cell, dissecting the architecture of tumors with unprecedented resolution.